Recent Articles

August 21, 2014 3:02 pm
Cynthia Fox, Science Writer
As, all around them, everyone from Derek Jeter to the Kennedy family was dousing themselves in ice water for the ALS “Ice Bucket Challenge,” Harvard researchers announced last week they may have found an ALS therapy. Read more...      
August 20, 2014 11:10 am
Chris Plaford, CFA, Chief Executive Officer, Claravant Analytics LLC
According to industry estimates, the majority of drugs in development will never make it to FDA approval. While a lack of efficacy is often a key factor, many clinical programs are derailed due to avoidable setbacks that can cause delays and significantly increase costs. Read more...
August 19, 2014 11:23 am
Sharon Benzeno, PhD, MBA, Senior Director, Business Development Bioinformatics, Elsevier
Big data is one of the hottest topics in R&D as its potential to accelerate successful drug development becomes more widely recognized. Part 2 of this two-part article analyses the new data-driven decision-making approaches make a difference to life science R&D. Read more...
August 18, 2014 3:14 pm
Cynthia Fox, Science Editor
A scientist has found that a compound, LY-411575, can restore 20% of hearing in deaf mice, or ten decibels. Since electroacoustic hearing aids, at best, improve hearing by five decibels, there is a “good chance” the work will lead to help for deafened patients.
August 15, 2014 9:09 am
Sharon Benzeno, PhD, MBA, Senior Director, Business Development Bioinformatics, Elsevier
Big data promises big insights for drug discovery and development, but its intrinsic value will be unlocked only if R&D organizations have the tools to make sense of it. Part 1 of this two-part article looks at how new models are changing the world of R&D. Read more...
July 31, 2014 1:21 pm
Louise Rozik, Editor
Scientists are accustomed to the fickle nature of research, but sometimes it can get to even the most seasoned researcher. One especially poignant example – the Cancer Genome Atlas – starts with the completion of the Human Genome Project in 2003. Read more...
July 24, 2014 10:44 am
Gur Roshwalb, M.D., Chief Executive Officer of Celsus Therapeutics
Recent years have witnessed the development of novel, non-steroidal anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs) focusing has been on one of the most sought-after pharmaceutical targets in inflammation research: the secretory phospholipase A2 family. Read more...
Subscribe to Drug Discovery & Development